UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

Phase 1

Completed

Conditions: Healthy Study Participants
Parkinson's Disease

Interventions: Drug: UCB0022
Other: Placebo

First Posted Date: 2021-04-30

Last Posted Date: 2023-03-30

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 100

Registration Number: NCT04867642

Locations: 🇬🇧
Up0091 001, London, United Kingdom

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Phase 2

Active, not recruiting

Conditions: Alzheimer's Disease

Interventions: Other: Placebo
Biological: Bepranemab

First Posted Date: 2021-04-30

Last Posted Date: 2024-08-02

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 466

Registration Number: NCT04867616

Locations: 🇪🇸
Ah0003 40280, Sant Cugat Del Valles, Spain
🇪🇸
Ah0003 40049, Sevilla, Spain
🇪🇸
Ah0003 40453, Terrassa, Spain

and more 100 locations

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: Alprazolam

First Posted Date: 2021-04-23

Last Posted Date: 2022-06-30

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 14

Registration Number: NCT04857307

Locations: 🇺🇸
Up0100 105, Memphis, Tennessee, United States
🇺🇸
Up0100 103, Honolulu, Hawaii, United States
🇺🇸
Up0100 106, Cincinnati, Ohio, United States

and more 5 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: rozanolixizumab
Other: Placebo

First Posted Date: 2021-04-02

Last Posted Date: 2024-03-07

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 32

Registration Number: NCT04828343

Locations: 🇬🇧
Up0106 001, London, United Kingdom

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

Phase 1

Completed

Conditions: Participants With Mild Asthma
Healthy Study Participants

Interventions: Drug: Alprazolam
Other: Placebo

First Posted Date: 2021-03-17

Last Posted Date: 2023-11-28

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 78

Registration Number: NCT04802746

Locations: 🇺🇸
Up0099 102, Raleigh, North Carolina, United States
🇺🇸
Up0099 101, North Dartmouth, Massachusetts, United States

Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: Alprazolam
Other: Placebo

First Posted Date: 2021-03-04

Last Posted Date: 2021-05-17

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 30

Registration Number: NCT04782388

Locations: 🇺🇸
Up0101 101, Anaheim, California, United States

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Certolizumab pegol

First Posted Date: 2021-02-05

Last Posted Date: 2024-02-12

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 33

Registration Number: NCT04740814

Locations: 🇺🇸
Ra0138 10025, Duncansville, Pennsylvania, United States
🇺🇸
Ra0138 1016, Memphis, Tennessee, United States
🇺🇸
Ra0138 1002, Covina, California, United States

and more 11 locations

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Phase 2

Active, not recruiting

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: bimekizumab

First Posted Date: 2021-01-22

Last Posted Date: 2024-11-15

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 41

Registration Number: NCT04718896

Locations: 🇵🇱
Ps0020 40334, Wroclaw, Poland
🇵🇱
Ps0020 40626, Bialystok, Poland
🇵🇱
Ps0020 40625, Lodz, Poland

and more 8 locations

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Phase 3

Active, not recruiting

Conditions: Epilepsy

Interventions: Drug: Brivaracetam

First Posted Date: 2021-01-20

Last Posted Date: 2024-10-04

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 70

Registration Number: NCT04715646

Locations: 🇮🇹
Ep0156 230, Roma, Italy
🇭🇺
Ep0156 210, Budapest, Hungary
🇯🇵
Ep0156 809, Shimotsuke, Japan

and more 23 locations

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: Zampilimab
Drug: Placebo

First Posted Date: 2021-01-12

Last Posted Date: 2022-07-19

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 16

Registration Number: NCT04705350

Locations: 🇬🇧
Up0105 001, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy